Treatment of congenital hypothyroidism

S. Segal, S. N. Cohen, J. Freeman

Research output: Contribution to journalArticle

Abstract

State and regional programs have been instituted in the United States and Canada for the screening of newborn infants for congenital hypothyroidism, and this topic was the subject of a recent report by the Committee on Genetics. The incidence of this disorder - averaged in several large series - is approximately 1 per 5,000 live births; therefore, these screening procedures represent a major advance in preventive medicine. Based on 3,160,000 live births in the United States in 1974, approximately 600 new cases of congenital hypothyroidism will be diagnosed each year through the screening programs and by recognition of affected infants by individual practitioners. These screening procedures result in earlier recognition of the disorder and thus a younger age at diagnosis; there also is increased knowledge about thyroid hormone homeostasis in the fetus and newborn infant. Therefore, it is appropriate to review dosage recommendations for treatment of infants with congenital hypothyroidism. In general, these recommendations are applicable to infants and young children with hypothyroidism regardless of the cause. The Committee on Drugs recommends the following: Physicians caring for children should participate in state, regional, or provincial screening programs for hypothyroidism and should maintain a high level of clinical suspicion to assure the earliest possible diagnosis of congenital hypothyroidism. Levothyroxine in a usual starting dose of 0.025 to 0.05 mg/day should be used for treatment. Dose adjustments should be made on the basis of patient response, particularly growth and development, and by measurements of serum T4 level, bone age, and/or other appropriate laboratory determinations. Consideration should be given to interactions with other drugs and disease states so appropriate dose adjustments will be made.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalPediatrics
Volume62
Issue number3
StatePublished - 1978
Externally publishedYes

Fingerprint

Congenital Hypothyroidism
Social Adjustment
Live Birth
Hypothyroidism
Pharmacy and Therapeutics Committee
Neonatal Screening
Preventive Medicine
Therapeutics
Thyroxine
Thyroid Hormones
Growth and Development
Canada
Early Diagnosis
Fetus
Homeostasis
Newborn Infant
Physicians
Bone and Bones
Incidence
Serum

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Segal, S., Cohen, S. N., & Freeman, J. (1978). Treatment of congenital hypothyroidism. Pediatrics, 62(3), 413-417.

Treatment of congenital hypothyroidism. / Segal, S.; Cohen, S. N.; Freeman, J.

In: Pediatrics, Vol. 62, No. 3, 1978, p. 413-417.

Research output: Contribution to journalArticle

Segal, S, Cohen, SN & Freeman, J 1978, 'Treatment of congenital hypothyroidism', Pediatrics, vol. 62, no. 3, pp. 413-417.
Segal S, Cohen SN, Freeman J. Treatment of congenital hypothyroidism. Pediatrics. 1978;62(3):413-417.
Segal, S. ; Cohen, S. N. ; Freeman, J. / Treatment of congenital hypothyroidism. In: Pediatrics. 1978 ; Vol. 62, No. 3. pp. 413-417.
@article{1a3d8fd064244e0f94abd8de5b2e7e8e,
title = "Treatment of congenital hypothyroidism",
abstract = "State and regional programs have been instituted in the United States and Canada for the screening of newborn infants for congenital hypothyroidism, and this topic was the subject of a recent report by the Committee on Genetics. The incidence of this disorder - averaged in several large series - is approximately 1 per 5,000 live births; therefore, these screening procedures represent a major advance in preventive medicine. Based on 3,160,000 live births in the United States in 1974, approximately 600 new cases of congenital hypothyroidism will be diagnosed each year through the screening programs and by recognition of affected infants by individual practitioners. These screening procedures result in earlier recognition of the disorder and thus a younger age at diagnosis; there also is increased knowledge about thyroid hormone homeostasis in the fetus and newborn infant. Therefore, it is appropriate to review dosage recommendations for treatment of infants with congenital hypothyroidism. In general, these recommendations are applicable to infants and young children with hypothyroidism regardless of the cause. The Committee on Drugs recommends the following: Physicians caring for children should participate in state, regional, or provincial screening programs for hypothyroidism and should maintain a high level of clinical suspicion to assure the earliest possible diagnosis of congenital hypothyroidism. Levothyroxine in a usual starting dose of 0.025 to 0.05 mg/day should be used for treatment. Dose adjustments should be made on the basis of patient response, particularly growth and development, and by measurements of serum T4 level, bone age, and/or other appropriate laboratory determinations. Consideration should be given to interactions with other drugs and disease states so appropriate dose adjustments will be made.",
author = "S. Segal and Cohen, {S. N.} and J. Freeman",
year = "1978",
language = "English (US)",
volume = "62",
pages = "413--417",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Treatment of congenital hypothyroidism

AU - Segal, S.

AU - Cohen, S. N.

AU - Freeman, J.

PY - 1978

Y1 - 1978

N2 - State and regional programs have been instituted in the United States and Canada for the screening of newborn infants for congenital hypothyroidism, and this topic was the subject of a recent report by the Committee on Genetics. The incidence of this disorder - averaged in several large series - is approximately 1 per 5,000 live births; therefore, these screening procedures represent a major advance in preventive medicine. Based on 3,160,000 live births in the United States in 1974, approximately 600 new cases of congenital hypothyroidism will be diagnosed each year through the screening programs and by recognition of affected infants by individual practitioners. These screening procedures result in earlier recognition of the disorder and thus a younger age at diagnosis; there also is increased knowledge about thyroid hormone homeostasis in the fetus and newborn infant. Therefore, it is appropriate to review dosage recommendations for treatment of infants with congenital hypothyroidism. In general, these recommendations are applicable to infants and young children with hypothyroidism regardless of the cause. The Committee on Drugs recommends the following: Physicians caring for children should participate in state, regional, or provincial screening programs for hypothyroidism and should maintain a high level of clinical suspicion to assure the earliest possible diagnosis of congenital hypothyroidism. Levothyroxine in a usual starting dose of 0.025 to 0.05 mg/day should be used for treatment. Dose adjustments should be made on the basis of patient response, particularly growth and development, and by measurements of serum T4 level, bone age, and/or other appropriate laboratory determinations. Consideration should be given to interactions with other drugs and disease states so appropriate dose adjustments will be made.

AB - State and regional programs have been instituted in the United States and Canada for the screening of newborn infants for congenital hypothyroidism, and this topic was the subject of a recent report by the Committee on Genetics. The incidence of this disorder - averaged in several large series - is approximately 1 per 5,000 live births; therefore, these screening procedures represent a major advance in preventive medicine. Based on 3,160,000 live births in the United States in 1974, approximately 600 new cases of congenital hypothyroidism will be diagnosed each year through the screening programs and by recognition of affected infants by individual practitioners. These screening procedures result in earlier recognition of the disorder and thus a younger age at diagnosis; there also is increased knowledge about thyroid hormone homeostasis in the fetus and newborn infant. Therefore, it is appropriate to review dosage recommendations for treatment of infants with congenital hypothyroidism. In general, these recommendations are applicable to infants and young children with hypothyroidism regardless of the cause. The Committee on Drugs recommends the following: Physicians caring for children should participate in state, regional, or provincial screening programs for hypothyroidism and should maintain a high level of clinical suspicion to assure the earliest possible diagnosis of congenital hypothyroidism. Levothyroxine in a usual starting dose of 0.025 to 0.05 mg/day should be used for treatment. Dose adjustments should be made on the basis of patient response, particularly growth and development, and by measurements of serum T4 level, bone age, and/or other appropriate laboratory determinations. Consideration should be given to interactions with other drugs and disease states so appropriate dose adjustments will be made.

UR - http://www.scopus.com/inward/record.url?scp=0018163172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018163172&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018163172

VL - 62

SP - 413

EP - 417

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

ER -